Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics · 2024
DOI: 10.58347/tml.2024.1697b ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Hyperphosphatemia, Renal Insufficiency, Chronic.
Abstract (Originalsprache)
The FDA has approved the sodium/hydrogen exchanger 3 (NHE3) inhibitor tenapanor (Xphozah – Ardelyx) to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy when phosphate binders are ineffective or as monotherapy when phosphate binders cannot be tolerated. Tenapanor is the first NHE3 inhibitor to be approved in the US for hyperphosphatemia. It was previously approved as Ibsrela to treat irritable bowel syndrome with constipation (IBS-C).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2024). Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1697b
Vancouver
Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1697b
BibTeX
@article{euvimed2024,
title = {Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2024},
doi = {10.58347/tml.2024.1697b}
}
EUVIMED